New Models for Peritoneal Dialysis Education

Shweta Bansal, MD, FASN
Associate Professor of Medicine
Division of Nephrology/Department of Medicine
University of Texas Health San Antonio, Texas
ISPD-NAC Day, ADC, March 5-8, 3021

Why we are talking about new models now

- Finally, the recognition of need for expanding treatment modalities available to patients with kidney failure.
- AAKHI established the goal of 80% of ESRD patients treated with either home dialysis or transplant by 2025.
- Transplantation accounts 30% and home hemodialysis – 2%
- PD will need to increase markedly from its current share of about 10%
 - Better experience and satisfaction
 - Quicker initiation avoiding the need for CVC
 - Better handling in patients with heart failure and pulmonary hypertension

Goals of New Models of PD Education

- Which must overcome
 - Social barriers
 - Clinical barriers
 - Financial barriers
- Which are directed towards
 - Patients and their care partners
 - Physicians including residents and fellows
 - Nephrologists as well as PCPs, access surgeons, cardiologists and endocrinologists
 - Nurses including students
 - Dieticians and social workers

Traditional Methods



Classroom style

Dialyspa® Patient Information Packet

WELCOME & INTRODUCTION

KIONEY DISEASE & ESRD

12 Causes of Kidney Failure 13 Main Risk Factors

16 End Stage Renal Disease

Treatment Options 17 Kidney Transplant Overview

211 Dialysis Facts and Key Terms

21 Dialysis for Your Health 22. Hemodialysis Pros. Cons and Care

15 Slages of Chronic Kidney Disease

14 Reducing Your Risk

DIALYSIS

Welcome Letter
 Patient Information User's Quice

10 Kidney Disease Facts and Key Terms 11 Symptoms of Kidney Failure

5 Guidelines for Total Wellness Health Benefits of Dialysis



- 54 Financial Assistance Programs

THE DIALYSPA DIFFERENCE

- 59 The Dialyspa Family

73 My Information User's Guide 75 Essential Information Record

© 2010 Distyspat Medical Center, LLC

- 83 Emergency Preparechess Guide

24 Pentaneal Dialysis Pros. Cons and Care

28 Nutrition Key Terms

26 Home Hemodialysis

- 42 What to Eat and What to Avoid

One to one



- 49 Your Social Worker
- 50 Common Emotional Effects of ESRD 52 Maintaining a Positive Outlook
- 56 Frequently Requested Phone Numbers 58 Additional Resources

- 60 The Dialyspa Patient-Centric Philosophy-
- 62. Dialosca Amenities 64 Dialysca Healthcare Features

My Information

Introduction
As of Describer 31,2007 of the approximately 386,000 billutory peritorical dialysis (CAPD)/am pointers undergoing dialysis in the Childed States, the point providence for peritorical dialysis (OTO) systems of the control of the 2000 september of the 2000 september

significant decline from the pack of 15% in the mil-strom initiation of therapy. A large proportion of dull 1888 (I). There are numerous seasons contributing to 1888 (I). There are numerous seasons contributing to the low insidence and prevalence of PD in this coun-ty. (2,3). There are concerned in particles paintin mor-bidity and mentality and the effect of a portiousle still down the 2-year period between XXX and 20A. U.S. reglorinologies. But seaving an in PD is interest to the HD could be a significant cause for the understanding to the River and the rate of 40 PS of the trial trial trials of 1970 weed belief and particularly in the U.S. nephrologies that survival on PD is interior to far to HD could be a significant come for the underturn ED portents, are excessive. There seems to be a
perception, among repletivelysis that there is modequate small-solute clearance by PD, especially in largeportions and in those with ne resolution learn familiarition followers and system issues as well as
quate small-solute clearance by PD, especially in largeportions and in those with ne resolution learn familiarition followers and system issues as well as
a particular therepy, especially when complicates
as particular therepy, especially when complicates
as particular therepy, especially when complicates
the naivy to subtle financial incommon unique to the
Chiefed States that on efficiation subdiply use. In the
current pay for exhalt-so-used replant providers
more "injectables" are used, and there is sake less of a
cost to put a patient on incontrar ID becomes the
infrastructure to although these. Curring to prevailing
greative, when U.S. repletedagies were surveyed returned to the compliance of
material and the compliance of
material and the compliance
states of
material and the
material and the
material and material and only in some
material and material and
material and material
material
material and material
ma

Handbook of PERITONEAL DIALYSIS Steven Guest MD

Gro

Peritoneal Dialysis First: Rationale

Kanol Chaudhan; ** Harbalati Sangha, * and Ramesh Khanna*

In-Depth Review

Current Challenges in Education for Any Learner



Different Types of Learners



Less Time



We must adapt as educator



Medical educator job roles

- Diagnostic Assessor
- Content Curator
- Technology Adopter
- Learner-centered navigator and professional coach
- Clinician role model or champion

Online Learning: E-learning




- The latest technologies have transformed our personal and professional lives.
- It has progressed at an exponential rate and presents an opportunity to enhance our work.
- Appeals to Millennial learners
- Incorporate interactivity and competition (increases engagement)
- Follows adult learning theory principles
- Provide scalable, convenient methods to practice skills such as PD administration
- In a safe, contextualized environment with
- directed feedback
- Individualized control of pace and timing of learning

Online Learning Modalities: E-learning

Videos




Courses



Podcasts



Video Conferencing




Serious gaming



British Colombia Resources for Health Professionals and Patients

http://www.bcrenal.ca/health-professionals/clinical-resources/peritoneal-dialysis






	BASIC SKILL	CAN PERFORM	CANNOT PERFORM	COMMENTS
1.	Pick up the PD solution bag and hold it over head for a count of 3.			
2.	Hang PD solution bag on IV pole.			
3.	Hold the transfer set and twist the clamp open and closed until it clicks.			
4.	Open a minicap package and place on the end of the transfer set without contamination.			
5.	Remove the mini cap from the transfer set.			
6.	Remove the colored ring from the PD solution bag.			
7.	Attach the red clamp anywhere along the PD tubing and snap it closed. Release the clamp to open.			
8.	Pick up the tongue depressor and snap it into 2 pieces.			
9.	Look at the picture of the home choice cycler below and record what is seen in the display screen.			



What is displayed on the screen?



PD Patient Training Modules

The BC Renal Peritoneal Dialysis Committee has developed a series of online, self-paced training modules covering various aspects of peritoneal dialysis care.

This series of eight modules is for the use of patients new to PD and for any patients who wish to review the procedures required for PD care. To access any of the modules, click on a title below.


- PD Module 1 Introduction to PD
- PD Module 2 Preventing Infection
- PD Module 3 CAPD
- PD Module 4 APD
- PD Module 5 Caring for your Exit Site



British Colombia Resources for Health **Professionals** and Patients

NephSim: A Free, Mobile-Optimized Nephrology Teaching Tool

J Grad Med Educ. 2019;11(6):708-712. doi:10.4300/JGME-D-19-00443.1





PICK YOUR CASE! ACID/BASE

IMAGE GALLERY

SUBMIT A CASE

Case 10: Diagnosis & Conclusions

Case Published: July 2018

Case 10 Index

Diagnosis: Peritonitis in Peritoneal Dialysis (PD)

Case Summary: Well done! This patient has peritonitis in the setting of peritoneal dialysis, one of the potential complications of PD. This young woman has had, until now, an uncomplicated 2 years on PD and is now presenting with abdominal pain worsening over 1 day. Just like with any non-PD patient, abdominal pain has a wide differential diagnosis, and we should be cautious not to anchor too quickly on peritonitis or other PD complications.

Let's briefly review the differential diagnosis for abdominal pain that should not be forgotten just because your patient is on PD!
Gynecologic


Urinary

Peritoneal

Intra-abdominal

Other

While keeping our eyes out for non-PD related pathology, it is important to act quickly with any suspicion for peritonitis. Looking at the PD fluid itself can also be helpful in making a diagnosis. PD fluid should be sent immediately for cell count with differential, gram stain, and culture.









GD

IMAGE GALLERY

SUBMIT A CASE ACID/BASE





Bloody (hemoperitoneum):

Coagulopathy Retrograde menstruation Ovulation Strenuous exercise Ovarian cyst rupture Adhesions Catheter-associated trauma



Normal

Home

∧ Nuts & Bolts of PD


Modes of PD

Clearance in PD

UF in PD

Peritoneal Transport Assessment

Modes of Peritoneal Dialysis




a


https://www.youtube.com/watch?v=kx7PZF A vs&feature=youtu.be&ab_channel=SuperSalms

Virtual PD Simulator

Course directors

- Aleksandra E.
 Olszewski, MD
- Deborah Stein, MD
- Traci Wolbrink, MD, MPH





Tactics

Case Studies

Your Patient Chart

Patient Information



Patient Name: Stephan


Patient Age: 6 months

Patient Weight: 6 kg

Location: PICU

History

Stephan, a 6-month-old infant, has just returned from surgical repair of congenital heart disease. His weight prior to surgery was 4 kilograms. The procedure required him to undergo cardiopulmonary bypass for repair. He also required a significant volume of fluids during and shortly after the procedure to maintain hemodynamics. He had an elevated creatinine prior to surgery, and a peritoneal dialysis catheter was placed electively with appropriate technique in the operating room. His weight is now recorded as 6kg. In the hours since returning from the procedure, the patient has not made any urine. Several trials of diuretics including an infusion have been unsuccessful and the infant is becoming progressively more difficult to ventilate.



0% Your Score

Task 1

Your patient's peritoneal dialysis catheter is in place and ready to use. Please select your initial dialysis prescription.

Click the continue button when you have completed your actions.

Continue

Patient Info

View Case History

Name: Stephan Weight: 6 kg

Age: 6 months Location: PICU



Table 3. Median time spent in simulator, with mean pre- and post-test scores for users completing the structured curriculum (n=300)

User	N	Median Time Spent in Simulator per User in Minutes (Interquartile Range)	Mean Pretest Score (SD)	Mean Post-Test Score (SD)	Mean Difference in Score (SD)	95% Confidence Interval	P Value
All users	300	85 (46-95)	29.5 (17.5)	66.0 (16.7)	36.4 (19.9)	34.1 to 38.6	< 0.001
Only nursing students	246	84 (42-94)	26 (14.6)	64.9 (16.1)	38.5 (19.8)	36.0 to 41.0	< 0.001
Nursing students excluded	54	91 (59-106)	44.0 (21.8)	71.0 (18.1)	27.0 (17.6)	22.2 to 31.8	< 0.001
Occupation					La Company		
Physician	32	96 (74-150)	44.6 (22.4)	69.7 (19.5)	25.0 (18.4)	18.4 to 31.7	< 0.001
Medical student	13	96 (91-101)	23.2 (11.3)	58.3 (16.4)	35.2 (18.3)	24.1 to 46.2	< 0.001
Resident	7	73 (21–77)	54.3 (16.5)	65.5 (20.8)	11.2 (14.2)	a	a
Fellow	3	192 (126-252)	60.0 (10.6)	93.0 (0)	33.0 (10.6)	a	a
Attending	9	158 (95-256)	63.0 (12.9)	81.4 (10.4)	18.4 (13.2)	a	а
Nurse	259	84 (42-94)	27.3 (15.5)	65.4 (16.3)	38.2 (19.7)	35.8 to 40.6	< 0.001
Nursing student	246	84 (42-94)	26.4 (14.6)	64.9 (16.1)	38.5 (19.8)	36.0 to 41.0	< 0.001
Registered nurse	13	81 (50-99)	43.7 (22.2)	75.8 (17.8)	32.2 (16.9)	21.9 to 42.4	< 0.001

^aSubanalyses of nursing students and non-nursing students are also presented due to the large representation by nursing student users in this dataset. Paired t test not performed on groups with <10 subjects.

Olszewski et al. Clin J Am Soc Nephrol 13: 900–906, 2018




Virtual or Augmented Reality

- "Perception of being physically present in a non-physical world".
- Patients or nurses finds themselves in a virtual environment in which they are enabled to move and interact with certain stimuli in a similar way to the real world.
- Training experience relies on VR technology which enables the user
 - To feel like being in a different environment (immersion)
 - To interact with the items and stimuli around her/him like in the real world (interaction).
- Benefit to trainees seeing and feeling a new task rather than reading about it step by step.

Virtual Reality Simulation in Peritoneal Dialysis Training: The Beginning of a New Era

Panagiota Zgoura^a Daniel Hettich^b Jonathan Natzel^b Fedai Özcan^a Boris Kantzow^b

^a Department of Nephrology, Klinikum Dortmund, Dortmund, Germany; ^b Weltenmacher GmbH, VR Training-Application, Düsseldorf, Germany



Standardized training

Faster and easier.

Follow up is pending

Established in endoscopy



Advanced PD Training

Joanna Lee Neumann RN CNN

Satellite Healthcare, San Jose Ca

Senior Healthcare Policy & Procedure Writer

ISPD NAC Committee Member

March 2021



Learning Outcome

Upon completion of this presentation, the participants will understand when to apply advanced PD training for nurses and PD patients as well as the relevant topics

Outline

- What is advanced PD training
- Resources to train PD nurses and patients
- Brief overview of how to conduct training
- Compare basic and advanced training for PD nurses
- When to do advanced training for PD patients

Disclosure

Joanna Lee Neumann RN CNN - None

Dr. Benner's Stages of Clinical Competence

Dr. Benner developed a concept known as "From Novice to Expert." This concept explains that nurses develop skills and an understanding of patient care over time from a combination of a strong educational foundation and personal experiences.

The theory identifies five levels of nursing experience:

- 1. Novice
- 2. Advanced Beginner
- 3. Competent
- 4. Proficient
- 5. Expert

"Advanced" definition

Ahead, further along in progress, complexity, knowledge, skill, etc

Advanced training takes place after the individual has completed the basic training.

- Might not be equivalent to:
 - **≻**Age
 - ➤ Years in practice
- Can be affected by
 - >Frequency of encountering
 - ➤ Past experience

2 Different Studies Conducted

Influence of Peritoneal Dialysis Training Nurses' **Experience on Peritonitis Rates**

- 200 consecutive inception PD patients in a single center from September 1999 through April 2003Patients
- Patients were followed up until death or October 30, 2006
- Effects of PD nurse trainers on the clinical outcomes of Grampositive peritonitis were evaluated

Conclusions: The finding of negative association between the trainers' length of time in practice and peritonitis incidence reminds us that active continued learning and applying principles of adult learning might be the answers for the nurses to teach the patients.

Ongoing active efforts are warranted to maintain competency in teaching PD, which in and of itself might not be acquired passively through accumulating experience. In addition, continuing education of trainers may be beneficial if it is shown that updated courses for the trainers can decrease the risk for Gram-positive peritonitis, a question that has not yet been examined.


Kai Ming Chow, Cheuk Chun Szeto, Man Ching Law, Janny Suk Fun Fung and Philip <u>Kam-Tao Li</u> CJASN July 2007, 2 (4) 647-652

Advanced Nursing Experience Is Beneficial for Lowering the Peritonitis Rate in Patients on Peritoneal Dialysis

- Observational cohort study followed 305 incident PD patients until a first episode of peritonitis, death, or censoring. Patients were divided into 3 groups according to the work experience in general medicine of their nurses
 - least experience (<10 years),
 - moderate experience (10 to <15 years),
 - advanced experience (≥15 years).
- Analyze the association of risks for all-cause and gram-positive peritonitis with patient training provided by nurses at different experience levels.

Conclusions: The experience in general medicine of nurses might help to lower the risk of gram-positive peritonitis among PD patients. These data are the first to indicate that nursing experience in areas other than PD practice can be vital in the training of PD patients

Zhikai Yang, Rong Xu, Min Zhuo, and Jie Dong Perit Dial Int. 2012 Jan-Feb; 32(1): 60-66.



Patient education: Peritoneal dialysis (Beyond the Basics)

- The Basics The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.
- **Beyond the Basics** Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.
- **Professional level information** Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.
- Author: John M Burkart, MDSection
- Editor: Thomas A Golper, MDDeputy
- Editor: Shveta Motwani, MD, MMSc, FASN
- Last updated February 27, 2020

Nursing Liaison Committee of ISPD




A Syllabus for Teaching Peritoneal Dialysis Patients and Caregivers Feb 2016

 Help PD nurses train patients and caregiver based on a consensus of training program reviews, utilizing current theories and principles of adult education.

• The course can be modified to meet individual trainee's needs.

Other Web Sites









SATELLITE HEALTHCARE ©2020 Satellite Healthcare Proprietary and Confidential

Training 101

- Utilize adult learning principles
- Identify the preferred learning style of the trainee
- Adjust teaching style to assist trainee to learn
- Identify learner's readiness and barrier to learn
- ❖Be a mentor, not just another senior staff who shows and tells

Adult Learning Principles

Andragogy

1. Need to know	The value of the learning in their lives
2. Need to take responsibility	Empower them to learn and take responsibility
3. Bring experience to learning	Respect and value the experience and utilize it wisely
4. Ready to learn	One of the most important factors. Take the moment
5. Task-oriented	Teach as the "task happens"

Adult Learning," by Malcolm S. Knowles

VARK theory of Learning Styles

VARK theory of learning styles

by Fleming and Mills' is very conductive to patient education

Determine the learner's learning style

- Visual
- Auditory
- Read or Write
- Kinesthetic

There are also articles to turn the theory down!



Learning Style and Teaching Style

Be flexible and be willing to adjust the teaching style to meet the learner

Be other-centered

Be observant

Individualized

Ask questions, get feedback

PDCA

Adjust and evaluate

There is no "one size fits all"

SATELLITE HEALTHCAR

Assessment and Evaluation

Assess and evaluate the nurse's or patient's level of understanding before providing further training

- Formal
- Informal

Confirm Basic knowledge

Ask open-ended questions

Observe procedures performed


Read documentation






Advanced PD training

Apply solution to real-world situations





BASIC

- 1. Complete a clinic visit
- Conduct medication review

3. Perform PD exit site care

- Ask the patient open-ended questions, read the home dialysis logs and provide appropriate and relevant care and education
- Explain the uses and side effects of the medications. Skillfully ask the patient questions to confirm compliance
- Carefully examine the PD exit site and identify any risk factors, which can cause exit site infection and then educate the patient

BASIC

- 1. Teach the patient to perform PD exchanges
- 2. Treat a PD exit-site infection according to the protocol and the nephrologist's order
- 3. Treat peritonitis as ordered

- Utilize the understanding of the physiology of peritoneal dialysis and perform trouble shooting
- 2. Perform more frequent PD exit-site check to assess the patient's response to treatment and make appropriate adjustments. Find the root cause of the infection and conduct focused training / retraining to emphasize prevention
- Interpret the PD effluent culture result and trend the effluent cell count results. Assess the patient's response to treatment and make appropriate adjustments. Find the route cause of the peritonitis and conduct focused training / retraining to emphasize prevention

BASIC

- Perform venipuncture and blood draw as ordered. Send the results to the nephrologist
- 2. Perform regular monthly and / or weekly clinic visit

- Trend all the lab results and be able to identify variances. Competent in managing: anemia and mineral bone disease. Identify the need for immunization. Early recognition of change in adequacy and be proactive in reporting and changing prescription
- Utilize case management skill to take care of the patient as a whole. Work with the interdisciplinary team to establish individualized plan of care. Be able to communicate with the patient and / or care partner effectively. Identify the opportunity and conduct "advanced training" for the patient

BASIC

1. Perform Peritoneal **Equilibration Test** correctly

- 1. Be able to identify incorrect results and not to utilize incorrect results to model the patient prescription
- 2. Be able to utilize the PET result to customize and individualize the patient's PD prescription
- 3. Recognize the signs and symptoms to call for a repeat PET

BASIC

1. Train the patient on how to use the PD cycler

ADVANCED

1. Monitor the patient remotely by accessing the treatment record after the completion of the treatment. (Machine with cloud based data – AMIA). Be able to analysis the record and be proactive in identifying potential problems. Example: Catheter flow, ultrafiltration, constipation, compliance, operator's error, etc. Then execute early intervention to reduce the potential for complications that can lead to hospitalizations.

How to Conduct Advanced PD Nurse Training

- Classes
- Journals
- Conferences
- Nephrologist / Medical Directors guided case studies
- Webinars
- On site training or mentoring

Tell me and I forget. Teach me and I remember. Involve me and I learn

PD Patients

ISPD Guidelines / Recommendations -

A syllabus for Teaching Peritoneal Dialysis to Patients and Caregivers

At the end of the training, the patient and / or caregivers:

- Is able to safely perform PD procedures using aseptic technique for connections
- Recognizes contamination and verbalizes appropriate action
- Identifies modification of fluid balance and its relationship to hypertension / hypotension
- Can detect, report and manage potential dialysis complications using available resources
- Understands when and how to communicate with the home dialysis unit

Ana E. Figueiredo, Judith Bernardini, Elaine Bowes, Miki Hiramatsu, Valerie Price, Chunyan Su, Rachael Walker, and Gillian Brunier

Patient education: Peritoneal dialysis (Beyond the Basics)

- Patient education: Dialysis or kidney transplantation which is right for me? (Beyond the Basics)
- Patient education: Hemodialysis (Beyond the Basics)
- Patient education: Chronic kidney disease (Beyond the Basics)
- Patient education: Constipation in adults (Beyond the Basics)
- Patient education: High-fiber diet (Beyond the Basics)
- Patient education: Low-sodium diet (Beyond the Basics)

John Burkart, MD, Thomas Colper, MD, Shveta Motwani, MD

When?

- Any teaching moment
- Every clinic visit
- Review treatment log
- Review medications
- Infectious and non-infectious complications
- Before a vacation





When?

Any teaching moment

- During casual conversation identified knowledge gap
- During exit-site care demonstrate and reinforce the importance of hand washing before exit-site care
- During storm season, high fire danger, news of power outage emergency preparedness
- When the patient has vital signs outside of his/her normal range and needs adjustments
- When the patient has signs and symptoms of fluid retention such as increased weight and emema

When?

Every clinic visit

Review treatment log

 Read the treatment log with the patient and question variances. Ask open-ended questions and then followed by explanations

Review medications

- Ask open-ended questions:
 - "What is this medication for?"
 - "Do you know the dosage you are taking?"
 - "How many pills and how many time you take this per day?"
 - "Do you know the possible side effects or when you should stop taking it?"

SATELLITE HEALTHCARE ©2020 Satellite Healthcare Proprietary and Confidential CONFIDENTI

When?

During infectious and non-infectious complications

- Must ask all the questions in a non-threatening manner
- Explain the facts according to the patient's learning style
- Make relevant examples to help them understand
- Focus on prevention
- Avoid saying, "Don't you remember what I told you" or "I told you!"
- Continue to assess patient's knowledge during the subsequent visits

When?

Before a vacation

- Supplies arrangements
- Dialysis supplies and accessories to pack
- Dialysis clinic at the destination contact information
- Dialysis prescription and medication list
- What to do in case of emergency





Summary

Advanced PD Training

Review of basic

Beyond basic

Application

Trouble shooting

When to do it

- The right moment
- The right teaching skill / method to ensure understanding



References

- Patient education: Peritoneal dialysis (Beyond the Basics)
 Author: John M Burkart, MDSection, Editor: Thomas A Golper, MDDeputy,
 Editor: Shveta Motwani, MD, MMSc, FASN Last updated February 27, 2020
- Influence of Peritoneal Dialysis Training Nurses' Experience on Peritonitis Rates Kai Ming Chow, Cheuk Chun Szeto, Man Ching Law, Janny Suk Fun Fung and Philip Kam-Tao Li CJASN July 2007, 2 (4) 647-652
- Advanced Nursing Experience Is Beneficial for Lowering the Peritonitis Rate in Patients on Peritoneal Dialysis
 Zhikai Yang, Rong Xu, Min Zhuo, and Jie Dong Perit Dial Int. 2012 Jan-Feb; 32(1): 60–66.
- ISPD A Syllabus for Teaching Peritoneal Dialysis Patients and Caregivers Feb 2016



"Great mentorship is priceless."

Lailah Gifty Akita



Joanna Lee Neumann neumannj@satellitehealth.com

International Society of Peritoneal North American Chapter Peritoneal Dialysis: Insights and Innovation

Matthew Oliver MD MHS
University of Toronto
Sunnybrook Health Sciences Centre




Objectives

- 1. To provide a overview of PD use in North America
- 2. To review current challenges facing PD
- 3. To review innovative practices in PD

Declarations

- Speaking honorarium from Baxter Healthcare
- Advisory board for Janssen and Amgen
- Co-inventor of DMAR systems


PD use in Ontario over time



Home dialysis (25%) = Peritoneal Dialysis (21%) + Home hemodialysis (4%)


PD use in the U.S over time

Figure 1.6 Number of prevalent ESRD patients, by modality, 2000-2018




Home dialysis (13%) = Peritoneal Dialysis (11%) + Home hemodialysis (2%)

Incident PD use in the U.S.



The complexity of PD



The loss from PD




Figure 2. Hemodialysis transfer, kidney transplantation, and death over time for all incident peritoneal dialysis patients. The prevalence of each outcome is shown as the vertical height of the appropriate area at each time point on the horizontal axis.

N=29,573 PD starts

USRDS Data


Years: 2008-2011

During follow-up, 12,175 (41.2%) patients transferred to HD

One or more claims for peritonitis were present in 12,121 (28.5%) patients

Median time on PD = 22 months

The multifactorial causes of loss



The Kitchen Sink

Education

Peer support

More tech in the home

New Start Unit

Better patient training

Reduce Peritonitis

Urgent start PD

Prevent PD catheter malfunction


More home visits

Nephrologist PD insertion

Assisted PD

Strategic retreats

PD and COVID-19



PD and COVID-19


	All	HD	PD
No. of patients	3285	3160	125
Age at diagnosis, yr, median (IQR)	71.7 (60.6–80.5)	71.8 (60.8–80.6)	70.2 (59.4–78.5)
0–19	9 (0.3)	8 (0.3)	1 (0.8)
20-44	225 (6.8)	215 (6.8)	10 (8.0)
45-64	854 (26.0)	817 (25.9)	37 (29.6)
65-74	857 (26.1)	823 (26.0)	34 (27.2)
≥75	1340 (40.8)	1297 (41.0)	43 (34.4)
Sex			
Male	2077 (63.2)	1993 (63.1)	84 (67.2)
Female	1208 (36.8)	1167 (36.9)	41 (32.8)
Primary renal disease			
Glomerulonephritis	381 (11.6)	363 (11.5)	18 (14.4)
Diabetes	839 (25.5)	813 (25.7)	26 (20.8)
Hypertension/RVD	695 (21.2)	671 (21.2)	24 (19.2)
Other	1370 (41.7)	1313 (41.6)	57 (45.6)
Treatment modality			
HD	3160 (96.2)	NA	NA
PD	125 (3.8)	NA	NA
Year of KRT start, median (IQR)	2017 (2014–2018)	2017 (2013–2018)	2018 (2017–2019)

Adjusted 28-day Mortality HD 18.0 PD 21.6

Summary

- Most governments, regions and programs are trying to grow home dialysis
- Growth is flat or modest at both overall
- Peritoneal dialysis can have high rates of loss from a variety of reason (Jack of all trades)
- There are many proposed solutions

The way forward



Learning from standards

SONG-PD



1 CORE OUTCOMES

Critically important to all stakeholder groups Report in all trials

2 MIDDLE TIER

Critically important to some stakeholder groups Report in some trials

3 OUTER TIER

Important to some or all stakeholder groups Consider for trials



A PDOPPS ANCILLARY STUDY

Learning from standards

FY 2020/21 Q2 12-Month Peritonitis Rate


PROGRAM	12-MONTH RATE	PROGRAM	12-MONTH RATE
SHN	0.07	NHS	0.20
SJH	0.13	THP	0.21
HHS	0.13	KGH	0.25
RVV	0.14	PET	0.26
RVH	0.15	MAH	0.26
HRH	0.15	WRH	0.27
JHH	0.16	ТВН	0.27
OSM	0.16	SMH	0.28
WOH	0.16	LHC	0.28
LHS	0.17	SAH	0.29
UHN	0.17	GRH	0.30
HSN	0.17	ТОН	0.32
SBK	0.18	TDH	0.80
NBH	0.19	MGH	N/A
Ontario Health	ONTABIO	0.20	

Cases reported per Year at Risk

0.20ONTARIO

19

Learning from standards



Analytics

Apr 1/20 ORN PD Census = 64

- New starts 28
- Predialysis Clinic 17 (61%)
- KFRE>50%- 14(50%)
- Modality Coach referral- 17(61%)
- HD as bridge to LRT -0(0%)
- Assessed for PD- 24 (86%)
- 3. **Eligible for PD – 16** (67%)
- 4. **Offered PD – 16** (100%)
- **Chose PD** (PD catheter attempt) **-9** (56%)
- **Receipt of PD 9** (100%)
- None to receive PD in a future report

Additions: Not New starts

PD re-starts – 1

Transfers in- 1

HD to PD - 1

Total Ins (Additions + New starts): 12

PD **Population**

Other **Considerations**

HHD choice - 1

Jun 30/20 ORN PD Census = 69

- 7. Technique Failure 3(43%)
- ➤ Peritonitis 2(67%)
- ➤ UF failure 0 (0%)
- Catheter dysfunction 0(0%)
- ➤ Leak 0(0%)
- ➤ Exit site infection 0(0%)
- ➤ Tunnel infection 0(0%)
- \triangleright Failure to cope 0(0%)
- ➤ Other 1(33%)
- 8. Transplantation 1 (14%)
- **9. Death/Withdrawal 2** (29%)
- **10. Other loss 1** (14%)

Losses Sum = 7


Bringing more support for PD




Barriers to self-care PD

Layer 1 Layer 2 Layer 3 Abdominal scarring Hernias Ascites Incontinence Medical Diarrhea Insomnia Obesity Gastroparesis Contraindications to PD **Hearing loss** (Medical or Social) Frailty Visual loss Reduce mobility **Physical** Manual dexterity Strength to lift bags Language barriers Memory Anxiety Dementia Cognitive Barriers to self-care PD **Aphasia** Depression Schizophrenia (cannot be overcome by Learning disabilities support) **Employment** Caregiver for others Social **Small Living Space** Retirement homes Poor hygiene Unclean house

PD tasks being assisted



Innovative models of care



Technology



What is the role of technology to amplify the impact of assistance?

Characteristics	HC group, mean ± SD	AMIA group, mean ± SD	p value	
Number of training days	5.4±2.7	3.6±1.4	0.022	
Serum albumin, g/dL	3.6±0.42	3.4±0.37	0.092	
Serum phosphorous, mg/dL	5.0±1.6	5.5±1.4	0.348	
Calcium-phosphate product	45.4±12.3	48.9±12.2	0.387	
Hemoglobin, g/dL	10.1±3.1	10.9±1.9	0.337	
Dialysis adequacy, kt/V	2.5±0.8	2.3±0.6	0.414	

Machine Learning / Al

Disc. character. Gender Female 216 56 (25.9) 160 (74.1)		N	Not Eligible	Eligible
Disc. character. Gender Female 216 56 (25.9) 160 (74.1)		IN		
Gender Female 216 56 (25.9) 160 (74.1) Male 396 76 (19.2) 320 (80.8) Dialysis location Started dialysis in ICU 33 16 (48.5) 17 (51.5) Predialysis care Predialysis care Predialysis care Predialysis care Predialysis care Predialysis care 564 113 (20.0) 451 (80.0) Predialysis care(4 months) 526 101 (19.2) 425 (80.8) Predialysis care(12 months) 426 77 (18.1) 349 (81.9) Comorbidity Diabetes 336 81 (24.1) 255 (75.9) Other cardiac conditions 116 28 (24.1) 88 (75.9) Polycystic kidney disease 28 7 (25.0) 21 (75.0) Gastrointestinal bleeding 24 7 (29.2) 17 (70.8) Coronary artery disease 137 33 (24.1) 104 (75.9) Congestive heart failure 88 30 (34.1) 58 (65.9) Cancer 82 22 (26.8) 60 (73.2) Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)	Disc character		101 115 (70)	101 115 (70)
Female	25 1.5 4.7 4.11.11.11.41.41.11			
Male 396 76 (19.2) 320 (80.8) Dialysis location Started dialysis inpatient 260 82 (31.5) 178 (68.5) Started dialysis in ICU 33 16 (48.5) 17 (51.5) Predialysis care Predialysis care (4 months) 526 101 (19.2) 425 (80.8) Predialysis care(12 months) 426 77 (18.1) 349 (81.9) Comorbidity Diabetes 336 81 (24.1) 255 (75.9) Other cardiac conditions 116 28 (24.1) 88 (75.9) Polycystic kidney disease 28 7 (25.0) 21 (75.0) Gastrointestinal bleeding 24 7 (29.2) 17 (70.8) Coronary artery disease 137 33 (24.1) 104 (75.9) Congestive heart failure 88 30 (34.1) 58 (65.9) Cancer 82 22 (26.8) 60 (73.2) Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 <td>Senaci</td> <td>216</td> <td>56 (25.0)</td> <td>160 (74.1)</td>	Senaci	216	56 (25.0)	160 (74.1)
Dialysis location Started dialysis inpatient 260 82 (31.5) 178 (68.5)				
Started dialysis in patient 260 82 (31.5) 178 (68.5) Started dialysis in ICU 33 16 (48.5) 17 (51.5) Predialysis care Predialysis care(4 months) 526 101 (19.2) 425 (80.8) Predialysis care(12 months) 426 77 (18.1) 349 (81.9) Comorbidity Diabetes 336 81 (24.1) 255 (75.9) Other cardiac conditions 116 28 (24.1) 88 (75.9) Polycystic kidney disease 28 7 (25.0) 21 (75.0) Gastrointestinal bleeding 24 7 (29.2) 17 (70.8) Coronary artery disease 137 33 (24.1) 104 (75.9) Congestive heart failure 88 30 (34.1) 58 (65.9) Cancer 82 22 (26.8) 60 (73.2) Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612		390	70 (19.2)	320 (60.6)
Started dialysis in ICU 33 16 (48.5) 17 (51.5) Predialysis care Fredialysis care Predialysis care 564 113 (20.0) 451 (80.0) Predialysis care(4 months) 526 101 (19.2) 425 (80.8) Predialysis care(12 months) 426 77 (18.1) 349 (81.9) Comorbidity Diabetes 336 81 (24.1) 255 (75.9) Other cardiac conditions 116 28 (24.1) 88 (75.9) Polycystic kidney disease 28 7 (25.0) 21 (75.0) Gastrointestinal bleeding 24 7 (29.2) 17 (70.8) Coronary artery disease 137 33 (24.1) 104 (75.9) Congestive heart failure 88 30 (34.1) 58 (65.9) Cancer 82 22 (26.8) 60 (73.2) Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)		260	92 (21.5)	170 (60 5)
Predialysis care Predialysis care 564 113 (20.0) 451 (80.0) Predialysis care(4 months) 526 101 (19.2) 425 (80.8) Predialysis care(12 months) 426 77 (18.1) 349 (81.9) Comorbidity 336 81 (24.1) 255 (75.9) Other cardiac conditions 116 28 (24.1) 88 (75.9) Polycystic kidney disease 28 7 (25.0) 21 (75.0) Gastrointestinal bleeding 24 7 (29.2) 17 (70.8) Coronary artery disease 137 33 (24.1) 104 (75.9) Congestive heart failure 88 30 (34.1) 58 (65.9) Cancer 82 22 (26.8) 60 (73.2) Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR)				
Predialysis care 564 113 (20.0) 451 (80.0) Predialysis care(4 months) 526 101 (19.2) 425 (80.8) Predialysis care(12 months) 426 77 (18.1) 349 (81.9) Comorbidity Diabetes 336 81 (24.1) 255 (75.9) Other cardiac conditions 116 28 (24.1) 88 (75.9) Polycystic kidney disease 28 7 (25.0) 21 (75.0) Gastrointestinal bleeding 24 7 (29.2) 17 (70.8) Coronary artery disease 137 33 (24.1) 104 (75.9) Congestive heart failure 88 30 (34.1) 58 (65.9) Cancer 82 22 (26.8) 60 (73.2) Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) <tr< td=""><td></td><td>33</td><td>10 (48.3)</td><td>17 (31.3)</td></tr<>		33	10 (48.3)	17 (31.3)
Predialysis care(4 months) 526 101 (19.2) 425 (80.8) Predialysis care(12 months) 426 77 (18.1) 349 (81.9) Comorbidity Diabetes 336 81 (24.1) 255 (75.9) Other cardiac conditions 116 28 (24.1) 88 (75.9) Polycystic kidney disease 28 7 (25.0) 21 (75.0) Gastrointestinal bleeding 24 7 (29.2) 17 (70.8) Coronary artery disease 137 33 (24.1) 104 (75.9) Congestive heart failure 88 30 (34.1) 58 (65.9) Cancer 82 22 (26.8) 60 (73.2) Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1)		564	112 (20.0)	451 (90.0)
Predialysis care(12 months) 426 77 (18.1) 349 (81.9) Comorbidity Diabetes 336 81 (24.1) 255 (75.9) Other cardiac conditions 116 28 (24.1) 88 (75.9) Polycystic kidney disease 28 7 (25.0) 21 (75.0) Gastrointestinal bleeding 24 7 (29.2) 17 (70.8) Coronary artery disease 137 33 (24.1) 104 (75.9) Congestive heart failure 88 30 (34.1) 58 (65.9) Cancer 82 22 (26.8) 60 (73.2) Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5)				
Comorbidity				
Diabetes 336 81 (24.1) 255 (75.9) Other cardiac conditions 116 28 (24.1) 88 (75.9) Polycystic kidney disease 28 7 (25.0) 21 (75.0) Gastrointestinal bleeding 24 7 (29.2) 17 (70.8) Coronary artery disease 137 33 (24.1) 104 (75.9) Congestive heart failure 88 30 (34.1) 58 (65.9) Cancer 82 22 (26.8) 60 (73.2) Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8)		420	// (18.1)	349 (81.9)
Other cardiac conditions 116 28 (24.1) 88 (75.9) Polycystic kidney disease 28 7 (25.0) 21 (75.0) Gastrointestinal bleeding 24 7 (29.2) 17 (70.8) Coronary artery disease 137 33 (24.1) 104 (75.9) Congestive heart failure 88 30 (34.1) 58 (65.9) Cancer 82 22 (26.8) 60 (73.2) Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20)		224	04 (04.4)	255 (75.0)
Polycystic kidney disease 28 7 (25.0) 21 (75.0) Gastrointestinal bleeding 24 7 (29.2) 17 (70.8) Coronary artery disease 137 33 (24.1) 104 (75.9) Congestive heart failure 88 30 (34.1) 58 (65.9) Cancer 82 22 (26.8) 60 (73.2) Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1)	15100000			
Gastrointestinal bleeding 24 7 (29.2) 17 (70.8) Coronary artery disease 137 33 (24.1) 104 (75.9) Congestive heart failure 88 30 (34.1) 58 (65.9) Cancer 82 22 (26.8) 60 (73.2) Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.				
Coronary artery disease 137 33 (24.1) 104 (75.9) Congestive heart failure 88 30 (34.1) 58 (65.9) Cancer 82 22 (26.8) 60 (73.2) Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)			, ,	, ,
Congestive heart failure 88 30 (34.1) 58 (65.9) Cancer 82 22 (26.8) 60 (73.2) Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)				
Cancer 82 22 (26.8) 60 (73.2) Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)	Coronary artery disease			
Cerebrovascular disease 53 11 (20.8) 42 (79.2) Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)				
Per. Vascular disease 56 16 (28.6) 40 (71.4) C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)			3 6	, ,
C. O. lung disease 57 24 (42.1) 33 (57.9) TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)			3 7	
TOTAL 612 132 (21.6) 480 (78.4) Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)	Per. Vascular disease			
Numer. Character. N=612 Median (IQR*) Median (IQR) Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)	C. O. lung disease	57	24 (42.1)	
Age 64 (17) 60 (23.3) Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)		612	132 (21.6)	480 (78.4)
Body Mass Index (BMI) 28.7 (10.1) 27.5 (7.9) Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)	Numer. Character.	N=612	Median (IQR*)	
Creatinine 612 (242.5) 644.5 (291.5) Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)			64 (17)	60 (23.3)
Urea 31.1 (17.0) 31.4 (14.4) Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)	Body Mass Index (BMI)		28.7 (10.1)	27.5 (7.9)
Albumin 30 (10.8) 34 (9) Hemoglobin 92.5 (20.8) 96 (20) Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)	Creatinine		612 (242.5)	644.5 (291.5)
Hemoglobin 92.5 (20.8) 96 (20)	Urea		31.1 (17.0)	31.4 (14.4)
Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)	Albumin		30 (10.8)	34 (9)
Parathyroidhormone 29.8 (69.3) 53 (113.1) Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)	Hemoglobin		92.5 (20.8)	96 (20)
Phosphate 2.0 (0.8) 1.9 (0.7) Calcium 2.1 (0.3) 2.1 (0.3)			29.8 (69.3)	53 (113.1)
Calcium 2.1 (0.3) 2.1 (0.3)	Phosphate		2.0 (0.8)	1.9 (0.7)
			2.1 (0.3)	2.1 (0.3)
	Bicarbonate		20 (6)	20 (5)

	TP	TN	FP	FN	Acc.	F1 for E=0	F1 for E=1
ADD (confidence=95%)	457	47	85	23	82.35%	0.465	0.894
K-Means	275	86	46	205	58.98%	0.407	0.687

New perspectives

International Society for Peritoneal Dialysis practice recommendations: Prescribing high-quality goal-directed peritoneal dialysis

An incremental PD prescription consists of any of the following:

- (1) continuous ambulatory peritoneal dialysis (CAPD) with fewer than four dwells daily, <2-L dwell volume, or <7 d/wk or
- (2) automated PD with no day dwell, <10-L total daily dose, or <7 d/wk

Summary

- Optimizing and growing PD use is an significant challenge
- We need to improve our ability to measure outcomes so we can benchmark our practices and learn form each other
- New forms of support that leverage technology will play a major role as the population ages.
- Data form these technologies can be use to provide advanced analytics to improve our care.
- Shifting to more holistic, patient focused goals will expand methods of providing PD.
- Quality improvement and research will continue to show us innovative practices to improve patient care.

PD In Non-Traditional Patients

Jenny Shen, MD, MS
Assistant Professor Of Medicine
Division of Nephrology, Harbor-UCLA Medical Center
Annual Dialysis Conference 2021

Disclosures

• Grant from NIH

Learning Objectives

- To describe strategies for optimizing peritoneal dialysis in obese patients.
- To understand the potential pitfalls and advantages to peritoneal dialysis as the modality for patients with cirrhosis.
- To appreciate the special considerations for peritoneal dialysis in patients with polycystic kidney disease.
- To identify individuals who may be candidates for assisted peritoneal dialysis.

Concerns about Obesity & PD

- Obese patients cannot be adequately dialyzed with PD because of their volume
- Obese patients will have many infections because of their body habitus

Optimizing PD for Obese Patients

- PD catheter placement
 - Stencil with the patient upright to judge beltline and potential pannus interference
 - Pre-sternal catheters another option
- PD prescription
 - Larger volumes
 - Take advantage of residual kidney function
 - Plan ahead for transitions to HD

Concerns about Cirrhosis and PD

- Increased risk of peritonitis
- Increased loss of protein

Potential Advantages to PD in Cirrhosis

- No anti-coagulation
- Less hemodynamic instability
- No need for therapeutic paracenteses

Optimizing PD for Cirrhosis

- Do not drain all of the fluid initially (take off slowly over a week)
- Extra vigilance for infections

Concerns about PKD and PD

- Not enough surface area for adequate dialysis
- Increased intra-abdominal pressure leading to leaks
- Increased infections from colonic diverticuli

Optimizing PD for PKD

- Nephrectomy not necessary (may even reduce residual kidney function)
- Use supine PD as much as possible
- No data showing there is an increased risk of infection

Concerns about Patients who Cannot Perform Self-Care

- Poor eyesight (common in older patients & those with diabetes)
- Cognitive difficulties (difficult to learn PD)
- Frail (too weak or not enough dexterity to manage bags, connections)

Assisted PD

Who?

- Family, friends
- Paid caregivers
- Does not need to be a nurse-can be trained just as the patients are

• When?

- Household members usually can manage CAPD or APD
- Paid caregivers can come twice a day for APD to connect at night and then disconnect in the AM